Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan-Mar;3(1):e24490.
doi: 10.4161/biom.24490. Epub 2013 Jan 1.

Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel

Rachel Ruckdeschel Smith  1 , Eduardo Marbán  2 , Linda Marbán  1
Affiliations
Review

Enhancing retention and efficacy of cardiosphere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel

Rachel Ruckdeschel Smith et al. Biomatter. 2013 Jan-Mar.

Abstract

Cardiosphere-derived cells (CDCs) are under clinical development and are currently being tested in a clinical trial enrolling patients who have undergone a myocardial infarction. CDCs are presently administered via infusion into the infarct-related artery and have been shown in early clinical trials to be effective agents of myocardial regeneration. This review describes the administration of CDCs in a hyaluronan-gelatin hydrogel via myocardial injection and the subsequent improvements in therapeutic benefit seen in animal models. Development of a next generation therapy involving the combination of CDCs and hydrogel is discussed.

Keywords: ALLSTAR trial; CADUCEUS trial; cardiosphere-derived cells; hyaluronan-gelatin hydrogel; myocardial infarction.

PubMed Disclaimer

Figures

None
Figure 1. CDC surface markers compatible with hydrogel. Representative flow cytometry histograms showing expression of CD49a (A), CD49b (B), CD49c (C) and CD44 (D) in CDCs (in blue). Isotype controls are shown in red.
None
Figure 2. CDC survival in the hydrogel. (A and B) Representative fluorescent micrographs showing live (Calcien-AM: green) and dead (EthD: red) staining of CDCs cultured in Hystem™ and Hystem-CTM for 7 d. (C) CCK-8 assay quantifying cell survival rates in HystemTM (black bars) or Hystem-CTM (green bars) (n = 3). * indicates p < 0.05 when compared with HystemTM.
None
Figure 3. Enhanced cell engraftment by delivering CDCs in Hystem-CTM. (A and B) Representative confocal images showing engraftment of DiI-labeled human CDCs (red) 24 h after injection into post-MI mouse hearts. (C) Quantitative PCR analysis of cell engraftment rates in the mouse hearts 3 weeks post injection (n = 3). * indicates p < 0.05 when compared with “CDC in PBS.”
None
Figure 4. Cardiac function and heart morphometry. (A) Changes of left ventricular ejection fraction (LVEF) measured by echocardiography from baseline to 3 weeks in each group. (B) Quantitative analysis and LV morphometric parameters of Masson’s trichrome images (n = 3–5 mice per group). * indicates p < 0.05 when compared with Control. ** indicates p < 0.05 when compared with any other group.
None
Figure 5. Promotion of angiogenesis by CDC/hydrogel transplantation. (A) Representative confocal images showing α smooth muscle actin-positive vasculature in the hearts receiving various treatment products. (B) Quantitation of α smooth muscle actin-positive vasculature in various groups (n = 5 mice per group). * indicates p < 0.05 when compared with Control. ** indicates p < 0.05 when compared with any other group. Bar = 200 µm.
See this image and copyright information in PMC

References

    1. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115:896–908. doi: 10.1161/CIRCULATIONAHA.106.655209. - DOI - PubMed
    1. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895–904. doi: 10.1016/S0140-6736(12)60195-0. - DOI - PMC - PubMed
    1. Malliaras K, Li TS, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation. 2012;125:100–12. doi: 10.1161/CIRCULATIONAHA.111.042598. - DOI - PMC - PubMed
    1. Smith RR, Kreke M, Malliaras K, Kanazawa H, Huang CH, Valle I, et al. Allogeneic cardiosphere-derived cells are safe and effective in a pig model of myocardial infarction. American Heart Association Annual Scientific Sessions 2012.
    1. Tseliou E, Pollan S, Malliaras K, Terrovitis J, Sun B, Galang G, et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol. 2013;61:1108–19. doi: 10.1016/j.jacc.2012.10.052. - DOI - PubMed

MeSH terms

LinkOut - more resources